Source: Annual Congress 2011 - T-cell subsets
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Profita, L. Riccobono, R. Gagliardo, C. DiSano, A. M. Montalbano, G. D. Albano, A. Ferlisi, A. Bonanno, P. Chanez, M. Gjomarkaj, S. La Grutta (Palermo, Italy; Marseille, France). IL-17 and Th17-cells as markers of disease progression in pediatric allergic diseases. A therapeutic approach in an "in vitro" models. Eur Respir J 2011; 38: Suppl. 55, 1832

Member's Comments

No comment yet.

Related content which might interest you: Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations Source: Eur Respir J, 50 (4) 1602434; 10.1183/13993003.02434-2016 Year: 2017 Subphenotyping COPD: is it relevant for therapeutic intervention and disease outcome? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 Th-17 cytokine profile in a Greek asthmatic population. Correlation with asthma severity and biomarkers of inflammation. Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 T-cell co-stimulatory molecules: novel targets for the treatment of allergic airway disease Source: Eur Respir J 2007; 30: 383-390 Year: 2007 Anti-Th2 cytokines inhibit progression in a murine model of childhood asthma Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 The level of anti-inflammatory cytokine IL-10 in patients with chronic obstructive pulmonary disease of varying severity Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 ST2 gene knockout attenuates allergic airways disease Source: Annual Congress 2006 - Immunological mechanisms in cell recruitment to the lungs Year: 2006 The future of targeted therapies for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005 Role of systemic inflammation mediated by IL-6 and TNF-alpha cytokines in chronic obstructive pulmonary disease and its progression: A three year follow up study Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Optimising disease models for lung diseases and drug development Source: International Congress 2015 – Development and application of new approaches for respiratory disease research Year: 2015 Elevated circulating CTLA-4 level in patients with COPD is related to systemic inflammation and disease severity Source: Annual Congress 2013 –COPD: markers and inflammation Year: 2013 Biological and therapeutic implications of the united airways disease concept Source: Annual Congress 2005 - PG18 - Inter-relationships between upper and lower airway diseases Year: 2005 Clinical markers of disease severity in the assessment of airway inflammation in patients with persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 335s Year: 2001 Pathogenesis of occupational asthma, including genetic factors Source: Annual Congress 2005 - Occupational asthma Year: 2005 Periostin as a marker of Th2-related inflammation in patients with different types of chronic obstructive airway disease Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 The relationship between bronchial inflammation and markers of disease progression in COPD Source: Eur Respir J 2003; 22: Suppl. 45, 179s Year: 2003 Prognosis: what is the contribution of inflammation to the decline in lung function in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007 The adaptive immune system, autoimmunity and COPD: lessons from human studies Source: Annual Congress 2007 - T- and B-cells in COPD: a role for adaptive immunity in the pathogenesis of COPD? Year: 2007